Contact Information

Department Information

Cardiology

Principal Investigator

Elizabeth Ofili, MD

.

Coordinator

JoAnn Cross, RN

.

 

Clinicaltrials.gov Details

Identifier

NCT01877915/Heart Failure

First Received Date

June 12, 2013

View on Clinicaltrials.gov

 

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)

Active

Purpose

The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.

Start Date

August, 2014

End Date

December 2018

Investigator(s)

Elizabeth Ofili, MD

Interventions

Drug:  Rivaroxaban

Drug: Placebo

Other: Standard of care of heart failure and coronary artery disease

Eligibility

Ages Eligible for Study: 18 years and older (Adult, Senior)

Sexes Eligible for Study: All

Accepts Healthy Volunteer: No